127919-32-8Relevant articles and documents
Synthesis of oxazoles by silver catalysed oxidative decarboxylation-cyclization of α-oxocarboxylates and isocyanides
Ma, Yiyang,Yan, Zhiyuan,Bian, Changliang,Li, Ke,Zhang, Xiaowen,Wang, Mengfan,Gao, Xinlong,Zhang, Heng,Lei, Aiwen
, p. 10524 - 10527 (2015/06/25)
A silver catalysed synthesis of oxazoles by the oxidative decarboxylation-cyclization of α-oxocarboxylates and isocyanides was developed. This method provided a novel strategy to construct oxazole rings compared to traditional methods. Mechanistic investigations such as operando IR, EPR and radical inhibition experiments were carefully done and confirmed the acyl cation and Ag(ii) as the intermediates in this transformation, and the involvement of a radical decarboxylative process.
OXAZOLE TYROSINE KINASE INHIBITORS
-
Page/Page column 130-131, (2009/01/20)
The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1 : provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
COMPOUNDS FOR TREATING AND PREVENTING COGNITIVE DISEASES AND DEPRESSION AND METHODS OF MAKING SAME
-
, (2008/06/13)
Ethylenediamine monoamides of the formula R--CO--NH--CH2 --CH2 --NH2. wherein R is one of groups in which R1 is phenyl monohalophenyl, monolower-alkylphenyl, monolower-alkoxypheynl, monotrifluoromethylphenyl, monocyanophenyl or monoaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R2 is hydrogen, halogen or amino, R3, R5 and R7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R4 and R6 each are hydrogen or amino and R8 is hydrogen or lower-alkyl, as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders
